VOLITIONRX LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.616 USD | -0.19% |
|
-10.07% | -14.09% |
| Mar. 26 | Transcript : VolitionRx Limited, Q4 2023 Earnings Call, Mar 26, 2024 | |
| Mar. 26 | VolitionRx Limited announced that it has received $0.1 million in funding | CI |
Presentation Operator MessageOperator (Operator)Hello and welcome to VolitionRx Limited Second...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
VolitionRx Limited is a multi-national epigenetics company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.616
USD
Average target price
3.725
USD
Spread / Average Target
+504.71%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -14.09% | 50.55M | |
| +39.11% | 3.16B | |
| -20.67% | 2B | |
| -40.59% | 1.96B | |
| -29.30% | 1.46B | |
| +11.45% | 966M | |
| -6.33% | 718M | |
| -30.75% | 430M | |
| -51.02% | 348M | |
| -2.58% | 286M |
- Stock Market
- Equities
- VNRX Stock
- News VolitionRx Limited
- Transcript : VolitionRx Limited, Q2 2021 Earnings Call, Aug 12, 2021
